Needham & Company
View Older Stories
-
Needham & Company Upgrades Vertex (VRTX) to Buy Ahead of CF Triple Regimen Data
-
Vertex (VRTX) Success Already Priced in the Stock, Needham & Company Says
-
Needham & Company Downgrades Vertex (VRTX) to Hold
-
Vertex (VRTX) PT Raised to $115 at Needham & Company
-
Needham & Company Discusses Vertex (VRTX) Phase 2 Trial of Ivacaftor in CF
-
Vertex (VRTX) Bullish Stance Reiterated at Needham & Company after Q1 Results, Encouraging VX-661-Ivacaftor Phase 2 Data
-
Pre-Open Stock Movers 12/19: (ALIM) (AKS) (ORCL) Higher; (CIE) (GIG) (FB) Lower (more...)
-
Vertex (VRTX) Bullish Stance Maintained after NACFC - Needham & Company
-
Needham & Company Maintains Bullish View on Vertex (VRTX) Following Q2 Earnings
-
Needham & Company Keeps Buy on Vertex (VRTX) Despite Partial Clinical Hold
-
Vertex (VRTX) PT Goes to $95 at Needham & Company after Strong Data
-
Analyst Says Vertex (VRTX) Drug Data Shows "At Least Moderate Impact"
-
Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Incivek Sales Continue to Fall, But Initial ALS-2200 Data Are Encouraging
-
Needham & Company Maintains a 'Buy' on Vertex (VRTX); Adjusting Q2 Lower, But Positive on Cash Flow
-
Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Combination Trial in CF Encouraging
-
Needham & Company Maintains Bullish Stance on Vertex (VRTX) Despite Weaker Data
-
Notable Analyst Rating Changes 05/08: (VRTX) (XCO) (EA) Upgraded; (EP) (BP) (AMX) Downgraded
-
Needham & Company Upgrades Vertex (VRTX) to Buy; Positive Interim VX-809/Kalydeco Results; Large Market Opp
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Q1 Preview
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Surprisingly Early Approval of Kalydeco for G551D Cystic Fibrosis
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); AASLD Meeting Update
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Incivek Sales Exceed Expectations Again, But Growth Appears to Be Slowing
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Raising Incivek Sales Estimates, But Concerns Remain
-
Notable Analyst Rating Changes 05/26: (HST) (FITB) (CTSH) Upgraded; (RSH) (LULU) (CAVM) Downgraded
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); 1Q11 Review; Vertex Ready for Incivek Approval and Launch
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Telaprevir Gets Enthusiastic Endorsement from FDA Advisory Committee, But Concerns Remain
-
Needham & Company Maintains a 'Hold' on Vertex (VRTX); Positive VX-770 Phase 3 Outcome in CF, But High Investor Expectations for HCV Program
-
Needham & Company Downgraded Vertex (VRTX) to Hold
-
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Encouraging Top-Line Results from Phase 3 ADVANCE Trial
-
Needham & Company Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Room for Upside Around Phase 3 ADVANCE Results
-
Needham & Co Reiterates a 'Buy' on Vertex Pharmaceuticals (VRTX); Raises Price Target
-
Needham & Co Upgrades Vertex Pharmaceuticals (VRTX) to Buy